CARE Clinic Uses Multidisciplinary Approach For Geriatric Multiple Myeloma

Video

Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.

Multidisciplinary care is a major focus across cancer institutions. Having a team made up of radiation oncologists, nurses, patients advocates, and others is critical to providing optimal care in multiple myeloma, according to Ashley E. Rosko, MD.

Rosko, an associate professor in the Department of Internal Medicine at The Ohio State University, medical director of the Oncogeriatric Program at The Ohio State University Comprehensive Cancer Center – The James, and co-director of the Cancer and Aging Resiliency (CARE) Clinic at The James, emphasized the benefits of multidisciplinary care while also outlining some of the guidelines used to guide practice at her institution.

Rosko spoke with CancerNetwork® during an Around the Practice® program which focused on current treatment options for patients with multiple myeloma. During the conversation, Rosko highlighted the CARE clinic of which she is co-director and how her and her team aim to help improve treatment for older patients with multiple myeloma.

Transcript:

When it comes to multidisciplinary care models, I co-direct the Cancer and Aging Resiliency [CARE] Clinic, which [provides] multidisciplinary care for older adults with cancer. [In particular], this clinic affords [opportunities] for patients who are coming into transplant. All patients 70 years and older who are undergoing autologous stem cell transplant are seen in our multidisciplinary care models. This provides an opportunity for patients to have their age-related health needs met [in an optimal way].

As an example, when a patient is newly diagnosed with multiple myeloma, they may be losing weight, they may be in pain, and their physical function may be lessened over [time]. In that clinic, we have a 7-member team that’s able to optimize those factors related to their cancer and also related to health. We have a nutritionist, we have a pharmacist, we have a physical therapist, and we have a nurse who specializes in cognitive impairment.

We have a case manager who talks about things like access and transportation to and from the clinic. We talked about the quality of life and important aspects for patients newly diagnosed with multiple myeloma. These multidisciplinary care models are important for patients to be able to have the best trajectory during their cancer journey. As such, this information is fed back to the transplant physicians and to the rest of the team in order to be able to define a treatment plan that is unique to the patient. Some patients will elect to go on to transplant and some patients need further optimization prior to their transplant.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content